Bliss GVS Pharma (BLISSGVS)

FairStock Score: 36/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Debt-to-equity of only 0.04, giving a strong, conservative balance sheet
• Piotroski F-Score of 7/9 indicates decent financial health and no major red flags
• Positive profitability with latest quarter net profit of ₹25 Cr on sales of ₹218 Cr
• Operating efficiency as reflected by ROCE of 11.72% being higher than ROE

Concerns

• ROE of just 7.41% is weak for a pharmaceutical company, indicating poor shareholder returns
• Sales and profit growth of 3.72% and 3.77% are barely ahead of inflation, making it a slow grower
• P/E of 20.30 and PEG of 5.42 suggest the stock is expensive for single-digit growth
• Dividend yield of only 0.24% offers almost no income cushion while waiting for growth

AI Analysis

When I look at Bliss GVS Pharma, I see a business that fails my first test: what does it earn on the capital it employs? Return on equity is just 7.41%, and return on capital is 11.72%. Neither is poor enough to scream danger, but neither is close to the 15% or better I expect from a quality enterprise. The balance sheet is clean—debt to equity of 0.04—and the Piotroski F-Score of 7 suggests no obvious accounting distress. That is good, but it is not a reason to overpay. Growth is barely ahead of inflation: sales up 3.72% and profits up 3.77%. For a pharmaceutical company, that is weak. At ₹268.95, the market cap is ₹2,243 crore, and the P/E is 20.30. With a PEG ratio of 5.42, the price already discounts years of far better performance than this business has shown. Book value is ₹97.12, so I am paying 2.77 times book for a 7.41% return on equity—that is not a bargain; it is a low-quality asset at a premium price. The stock has fallen from its 52-week high of ₹552.90 to ₹268.95, but a falling knife is not a margin of safety. The dividend yield is a negligible 0.24%, so I am not being paid to wait. Promoter holding at 35.36% is adequate but not commanding; minority shareholders should watch for capital allocation discipline. The latest quarter shows ₹218 crore sales and ₹25 crore net profit, but one quarter does not change the trajectory. In the end, this looks like a steady but mediocre compounder. I would only be interested at a materially lower price, perhaps closer to book value, and with evidence that return on equity and growth are both improving. Until then, I pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer